Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Suvorexant and Trauma Related Insomnia
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Howard University
- Target Recruit Count
- 41
- Registration Number
- NCT02704754
- Locations
- ๐บ๐ธ
Clinical Research Unit; Howard University Hospital, Washington, District of Columbia, United States
Suvorexant in Insomnia Co-morbid With Fibromyalgia
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 10
- Registration Number
- NCT02684136
- Locations
- ๐บ๐ธ
HFHS Sleep Disorders Ctr, Detroit, Michigan, United States
A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
- Conditions
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2019-02-27
- Target Recruit Count
- 74
- Registration Number
- NCT02669030
- Locations
- ๐บ๐ธ
Medical College of GA at Augusta Univeristy, Augusta, Georgia, United States
๐บ๐ธInstitute for Advanced Medical Research @ Mercer Univeristy, Atlanta, Georgia, United States
The Role of Orexin in Human Panic Disorder
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 3
- Registration Number
- NCT02593682
- Locations
- ๐บ๐ธ
UCSF Fresno Medical Education Program, Fresno, California, United States
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 61
- Registration Number
- NCT02527564
- Locations
- ๐บ๐ธ
Stanford University, Stanford, California, United States
Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- VA Palo Alto Health Care System
- Target Recruit Count
- 19
- Registration Number
- NCT02491788
- Locations
- ๐บ๐ธ
VA Palo Alto Health Care System, Palo Alto, California, United States
Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01300455
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01293006
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01059851
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01043926
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.